Physician profile
Sandra J Kreul
NPI 1194839332
$7,061.97
in general payments reported to CMS, 2019-2025
32 companies · $1,723 in 2025
The $1,723 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $716 · 2022: $1,482 · 2023: $1,242 · 2024: $1,898 · 2025: $1,723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,348 · Travel and Lodging: $471 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,347.84 |
| Travel and Lodging | $470.80 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $920.69 | 2023 | Linq II |
| Amgen INC. | $749.10 | 2021-2025 | Repatha, Repatha |
| Abiomed | $639.67 | 2023-2025 | Impella |
| Novo Nordisk INC | $586.24 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Novartis Pharmaceuticals Corporation | $505.24 | 2022-2025 | |
| Cvrx, INC. | $419.41 | 2022-2025 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $388.62 | 2021-2023 | Verquvo |
| Pfizer INC. | $302.79 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $269.62 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $266.69 | 2021-2023 | Uptravi |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $243.59 | 2021-2025 | Lifevest |
| Regeneron Pharmaceuticals, INC. | $217.36 | 2025 | Evkeeza |
| Astrazeneca Pharmaceuticals LP | $213.68 | 2022-2024 | Wainua, Farxiga |
| Impulse Dynamics (USA) INC. | $180.00 | 2024 | Optimizer |
| Alnylam Pharmaceuticals INC. | $145.13 | 2024-2025 | Amvuttra, Onpattro |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $139.41 | 2021-2024 | Xarelto |
| Regeneron Healthcare Solutions, INC. | $134.95 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $112.42 | 2024-2025 | |
| Abbott Laboratories | $105.16 | 2021-2022 | |
| Esperion Therapeutics, INC. | $94.63 | 2022-2025 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $78.61 | 2021-2022 | |
| Boston Scientific Corporation | $69.88 | 2021-2025 | Varithena Administration Pack |
| Scpharmaceuticals INC. | $53.90 | 2024-2025 | |
| Lexicon Pharmaceuticals, INC. | $41.66 | 2023-2024 | Inpefa |
| Cleerly, INC. | $34.24 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Kestra Medical Technology Services, INC. | $28.83 | 2022 | |
| Chiesi USA, INC. | $26.32 | 2023 | Kengreal, Cleviprex |
| Arbor Pharmaceuticals, INC. | $24.63 | 2021 | |
| Irhythm Technologies, INC. | $20.47 | 2022 | |
| Philips North America LLC | $19.48 | 2022 | |
| Amryt Pharma Holdings LTD | $16.65 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $12.90 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Kreul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.